A toxicologic pathology nonclinical safety assessment is a key factor in determining the safety of newly developed drugs. Global Pathology Support provides the services and facilities needed to perform these assessments. During a nonclinical safety assessment we maintain international standards such as GLP, provide consistent toxicologic pathology reports, and strict quality management.
30% of adverse effects undetected in a conventional toxicologic pathology nonclinical safety assessment
Most toxicologic safety assessments rely on dosing rodent and non-rodent species with a new drug. When applied for 1 month, this method identifies 90% of the adverse effects that will ever be detected in these kinds of assessments. This, however, is a distorted percentage because these studies do not account for the human factor. Translated to the human body, the concordance rate is about 70%. Therefore, the species, organs, anatomy, histology and drug class need to be accounted for in order to deliver an accurate toxicologic pathology nonclinical safety assessment. Global Pathology Support includes all of these factors to make a proper extrapolation for an accurate safety assessment.
Inquire about availability
A proper toxicologic pathology nonclinical safety assessment takes time. At the same time, your company needs results in order to proceed with clinical trials. That is why Global Pathology Support offers fast delivery by closely working with your R&D department. We are available 24/7 and offer the services you need, when you need them. Inquire about availability by calling at +31 (0)70-314 24 04.